Lankenau Medical Center first in Pennsylvania to offer new treatment option for abdominal aortic aneurysms
Lankenau Medical CenterDecember 7, 2020News Releases
Lankenau Medical Center, part of Main Line Health’s Lankenau Heart Institute, became the first hospital in the state of Pennsylvania to implant the ALTO® Abdominal Stent Graft System, a new treatment for abdominal aortic aneurysm. Vascular surgeon Robert J. Meisner, MD, FACS performed the implant.
The ALTO Abdominal Stent Graft System is a minimally-invasive treatment option for abdominal aortic aneurysm (AAA). While minimally invasive treatments have long been available for the treatment of AAA, the ALTO system is unique because of its design—the size of the implant allows surgeons to treat patients with small vessels and challenging access, and an integrated balloon feature makes for an easier seal and long-term durability. As a result, minimally invasive AAA treatment is available to a broader range of patients.
“To be the first in the state to offer this treatment to our patients is exciting. The ALTO has a superior design that makes it a preferable option for providers but its most important feature is that it offers improved outcomes and allows us to improve the quality of life and survival rate for more patients than ever before,” says Dr. Meisner.
The aorta is the body’s main artery, carrying blood from the heart to the rest of the body. Abdominal aortic aneurysm is an enlarged and weakened section, or “ballooning” of the aorta below the renal arteries that may require treatment to prevent it from bursting and causing serious internal bleeding. Abdominal aortic aneurysms often grow slowly with few—if any—symptoms and are more common among men age 65 and over, as well as people with a history of smoking or tobacco use. Depending on your personal health history, you may be eligible for an AAA screening.
Featuring a unique sealing technology, ALTO is the latest generation of low-profile polymer-based therapies for AAA treatment, offered exclusively by the Endologix Corporation. Endologix Inc. develops and manufactures minimally invasive treatments for aortic disorders. Additional information about the company can be found at www.endologix.com.
Founded in 1985, Main Line Health is a not-for-profit health system serving Philadelphia and its western suburbs. Main Line Health's commitment—to deliver advanced medicine for treating and curing disease, playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to be the region's premier choice for clinical care, research, and education. A team of more than 10,000 employees, 3,000 nurses and 2,000 physicians care for patients throughout the Main Line Health System.
At Main Line Health's core are four of the region's most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation's premier facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.
Main Line Health also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton, King of Prussia and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region's largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care, and service, including U.S. News & World Report's Best Hospitals, System Magnet® designation; the nation's highest distinction for nursing excellence and the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award. Main Line Health is committed to creating an environment of diversity, respect, equity, and inclusion, has proudly received awards in this area and has embraced the American Hospital Association's #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education, and research to help patients stay healthy and live their best lives.
The Lankenau Heart Institute is Main Line Health’s premier, comprehensive cardiovascular medicine and surgery program. The Lankenau Heart Institute brings together the clinical expertise of all four Main Line Health acute care hospitals and community cardiology practices to ensure that patients receive a level of quality, service, and experience that is unprecedented in the region. Through the system-wide coordination of services, the Lankenau Heart Institute delivers preventive, diagnostic, therapeutic, and rehabilitative cardiovascular services at each of our locations including Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital.
Lankenau Heart Institute continues to be a pioneer in the use of beating-heart techniques and robotic-assisted procedures for coronary artery revascularization, minimally invasive and transcatheter approaches for valve repair and replacement, and complex aortic surgeries. With our growing experience and focus on minimally invasive techniques, Lankenau Heart Institute has expanded participation in clinical trials year over year. Our physicians are frequently invited to participate in clinical/medical device trials, many of these designed to facilitate minimally invasive procedures/approaches.
With a collaborative team of expert consultative cardiologists, interventional cardiologists, electrophysiologists, cardiovascular surgeons and specially trained nurses and technologists, the Lankenau Heart Institute is dedicated to managing and treating patients with heart failure, aortic disease, coronary and peripheral vascular disease, heart rhythm disorders and valve disease. Our team of cardiologists and cardiac specialists provide patients and their families with expert cardiac care, close to home.
About Lankenau Medical Center
Lankenau Medical Center, a member of Main Line Health, is recognized as a national leader in advancing new options to diagnose and treat illness, protect against disease and save lives. Located on a 93-acre campus just outside of Philadelphia, Lankenau Medical Center is a 371-bed, not-for-profit teaching hospital that includes one of the nation’s leading cardiovascular centers; the Lankenau Institute for Medical Research, one of the few freestanding hospital-associated research centers in the nation; and the Annenberg Conference Center for Medical Education, that trains over 100 new physicians each year through nationally ranked residency and fellowship programs. Lankenau has received both regional and national recognition for its excellence in providing state-of-the-art, quality care. Lankenau Medical Center has been named among the top 10 hospitals in Pennsylvania and top five in the Philadelphia metro area in U.S. News & World Report’s Best Hospitals 2020–21, and was ranked as high-performing in abdominal aortic aneurysm repair, aortic valve surgery, colon cancer surgery, gastroenterology & GI surgery, geriatrics, heart bypass surgery, heart failure, hip replacement, knee replacement, lung cancer surgery and nephrology. Lankenau has achieved The Joint Commission’s Gold Seal of Approval for stroke care and breast cancer care and is one of the nation’s Top Performing Hospitals for heart attack, heart failure, pneumonia and surgical care. Lankenau has also been ranked for multiple years as one of the top 50 cardiovascular hospitals in the nation by Truven Health Analytics. Lankenau has also earned the highest distinction for excellence in nursing care, the American Nurses Credentialing Center Magnet® designation.